No Data
Obu Biotech: 2024 Annual Report
Obu Biotech: 2024 Annual Report Summary
Obu Biotech: Report for the first quarter of 2025
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced its first-quarter performance, with a net income of 74.3421 million yuan, a decrease of 3.71%.
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) released its first-quarter report for 2025, reporting a revenue of 2.28...
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ): In 2024, net income is expected to grow by 2.46% year-on-year, planning to distribute 1.2 yuan for every 10 shares.
On April 18, Gelonghui announced that Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) published its annual report for 2024. During the reporting period, the company achieved revenue of 0.925 billion yuan, an increase of 9.10% compared to the same period last year; the net income attributable to shareholders of the listed company was 0.318 billion yuan, an increase of 2.46% compared to the same period last year. A cash dividend of 1.2 yuan is distributed for every 10 shares to all shareholders.
Earnings Are Growing at Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) but Shareholders Still Don't Like Its Prospects
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) 29% Price Boost Is Out Of Tune With Earnings
